Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 55

The DOI matches its Crossref record.

Model‐based design and control of a small‐scale integrated continuous end‐to‐end mAb platform

Gomis‐Fons, Joaquín, Schwarz, Hubert, Zhang, Liang, Andersson, Niklas, Nilsson, Bernt, Castan, Andreas, Solbrand, Anita, Stevenson, Joanne, Chotteau, Véronique·2020·Biotechnology Progress

Abstract

A continuous integrated bioprocess available from the earliest stages of process development allows for an easier, more efficient and faster development and characterization of an integrated process as well as production of small‐scale drug candidates. The process presented in this article is a proof‐of‐concept of a continuous end‐to‐end monoclonal antibody production platform at a very small scale based on a 200 ml alternating tangential flow filtration perfusion bioreactor, integrated with the purification process with a model‐based design and control. The downstream process, consisting of a periodic twin‐column protein A capture, a virus inactivation, a CEX column and an AEX column, was compactly implemented in a single chromatography system, with a purification time of less than 4 hr. Monoclonal antibodies were produced for 17 days in a high cell density perfusion culture of CHO cells with titers up to 1.0 mg/ml. A digital twin of the downstream process was created by modelling all the chromatography steps. These models were used for real‐time decision making by the implementation of control strategies to automatize and optimize the operation of the process. A consistent glycosylation pattern of the purified product was ensured by the steady state operation of the process. Regarding the removal of impurities, at least a 4‐log reduction in the HCP levels was achieved. The recovery yield was up to 60%, and a maximum productivity of 0.8 mg/ml/day of purified product was obtained.

Overview

Integrity signals

Registry

Crossref · 10.1002/btpr.2995

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. Levine HL, 2017, The Development of Therapeutic Monoclonal Antibody Products
  2. 10.1016/j.jchromb.2006.07.037 · DOI · Paper page
  3. 10.1002/btm2.10061 · DOI · Paper page
  4. 10.1002/biot.201700721 · DOI · Paper page
  5. 10.1016/j.jbiotec.2016.12.005 · DOI
  6. 10.1002/bit.24584 · DOI · Paper page
  7. 10.1002/jps.24268 · DOI · Paper page
  8. 10.1016/j.biotechadv.2018.04.011 · DOI · Paper page
  9. 10.1002/btpr.2434 · DOI
  10. 10.1002/biot.201700691 · DOI
  11. 10.1016/j.jbiotec.2015.06.393 · DOI · Paper page
  12. 10.1002/biot.201800061 · DOI
  13. Jiang M, 2016, Integrated control of continuous (bio)pharmaceutical manufacturing, Am Pharm Rev, 19
  14. 10.1016/S0098-1354(00)00492-0 · doi:10.1016/s0098-1354(00)00492-0
  15. 10.1016/j.jbiotec.2019.12.017 · DOI · Paper page
  16. 10.1016/j.tibtech.2013.05.011 · DOI · Paper page
  17. 10.1016/j.jbiotec.2019.05.013 · DOI
  18. 10.1016/j.chroma.2009.09.017 · DOI
  19. 10.1016/j.chroma.2017.02.026 · DOI
  20. 10.1007/978-1-4471-6443-2_2 · doi:10.1007/978-1-4471-6443-2_2
  21. 10.1016/j.chroma.2018.03.060 · doi:10.1016/j.chroma.2018.03.060
  22. 10.1021/ie5023223 · doi:10.1021/ie5023223
  23. 10.1016/j.ijbiomac.2015.03.027 · DOI
  24. 10.1002/btpr.2871 · doi:10.1002/btpr.2871
  25. 10.1002/bit.21527 · DOI · Paper page
  26. 10.1002/btpr.2522 · DOI
  27. 10.1023/A:1025771421906 · DOI · Paper page
  28. 10.1002/bit.26069 · DOI
  29. 10.1080/10826068.2018.1446151 · DOI

Cited by

Metadata

Authors
Gomis‐Fons, J., Schwarz, H., Zhang, L., Andersson, N., Nilsson, B., Castan, A., Solbrand, A., Stevenson, J., & Chotteau, V.
Affiliations
  • Department of Chemical Engineering Lund University Lund Sweden
  • Department of Industrial Biotechnology School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology Stockholm Sweden
  • GE Healthcare Life Sciences Uppsala Sweden
  • Cobra Biologics, Analytical Development Södertälje Sweden
Venue
Biotechnology Progress
Publisher
Wiley
Published
2020-04-06
Volume
36
Issue
4
ISSN
  • 8756-7938
  • 1520-6033
Cited by
55
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.